


[Mobile ebook] Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry (Woodhead Publishing Series in Biomedicine)

# **Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry (Woodhead Publishing Series in Biomedicine)**

*William R Strohl, Lila M Strohl*  
*DOC | \*audiobook | ebooks | Download PDF | ePub*



[Download](#)

[Read Online](#)

#1896166 in Books Woodhead Publishing 2012-10-30 Original language: English PDF # 1 9.21 x 1.50 x 6.14l, 2.53 #File Name: 1907568379696 pages | File size: 66.Mb

**William R Strohl, Lila M Strohl : Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry (Woodhead Publishing Series in Biomedicine)** before purchasing it in order to gage whether or not it would be worth my time, and all praised Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry

(Woodhead Publishing Series in Biomedicine):

The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering. Goes beyond the standard engineering issues covered by most books and delves into structure-function relationships. Integration of knowledge across all areas of antibody engineering, development, and marketing. Discusses how current and future genetic engineering of cell lines will pave the way for much higher productivity.

An excellent balance between readability and depth of material.... The book is well referenced and provides plentiful opportunities to continue subject-specific learning., mAbs Journal. An excellent book describing many aspects of therapeutic antibody generation and the current market share of these drugs. It is an up-to-date evaluation of their production and clinical utility., Doody's s. About the Author. Dr William R. Strohl is Vice President of Biologics Research at Janssen RD Biotechnology Center of Excellence, and was previously a leader in Merck's efforts to discover therapeutic monoclonal antibodies, as well as in-licensing of therapeutic targets and technologies associated with monoclonal antibodies. He has over 100 publications and several patents to his credit, and has edited two books.